In Phase 3 outcome trials with novel TG-lowering agents, which patient populations should we be targeting?
Professor Ioanna Gouni-BertholdWatch the presentation >
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
